Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

991
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
991
Drug Therapy01:28

Drug Therapy

316
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
316
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

264
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
264
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

858
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
858
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.7K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.7K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

398
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
398

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Repressed Anxiety: A Concept Analysis.

Issues in mental health nursing·2026
Same journal

Dispelling Myths About Youth Vaping.

Issues in mental health nursing·2026
Same journal

Survey on Nursing Education and the Perceived Burden of Borderline Personality Disorder in France.

Issues in mental health nursing·2026
Same journal

"Un Dia de Conversación con Promotoras de Tejas": A Statewide, Spanish-Language CHW Conference in Texas and Its Impact on Mental Health.

Issues in mental health nursing·2026
Same journal

Speaking up in Nursing: What Policy Promises and Practice Delivers.

Issues in mental health nursing·2026
Same journal

Beyond Bullying: Digital Platforms, Power and the New Landscape of Violence Against Nurses.

Issues in mental health nursing·2026

Related Experiment Video

Updated: Feb 21, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.7K

Medication Adherence Using Medication Event Monitoring System Among Young Adults with Major Depressive Disorder.

Jia Xu1, Weiwei Zhao1, Pan Lin1

  • 1Department of Psychiatry, the Affiliated Brain Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, China.

Issues in Mental Health Nursing
|February 19, 2026
PubMed
Summary

Medication adherence in young adults with major depressive disorder (MDD) is influenced by factors like hospital readmissions and side effects. Older age, self-stigma, and negative drug attitudes predict lower adherence, aiding risk assessment.

More Related Videos

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.5K
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.6K

Related Experiment Videos

Last Updated: Feb 21, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.7K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.5K
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.6K

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Background:

  • Medication adherence is crucial for managing major depressive disorder (MDD).
  • Understanding adherence predictors in first-episode young patients is vital for effective treatment.
  • Low adherence can lead to relapse and poorer long-term outcomes in adolescent and young adult MDD.

Purpose of the Study:

  • To identify socio-demographic, clinical, and patient-reported factors associated with medication adherence in young patients with a first episode of MDD.
  • To develop a predictive model for identifying individuals at high risk of non-adherence.
  • To inform clinical strategies for improving medication adherence in this population.

Main Methods:

  • Prospective enrollment of 512 young patients with first-episode MDD.
  • Medication adherence tracked for 30 days using the Medication Event Monitoring System (MEMS).
  • Binary logistic regression analysis of socio-demographic factors, clinical variables, and patient-reported scores.

Main Results:

  • 69.3% of patients achieved MEMS adherence.
  • Increased risk of low adherence was associated with hospital readmissions, drug concentrations outside the therapeutic range, and severe side effects.
  • Older age, higher self-stigma scores, and negative drug attitudes were significant predictors of low adherence.
  • A prognostic index > 0.800 indicated a high risk of developing low adherence.

Conclusions:

  • Several factors significantly impact medication adherence in young MDD patients.
  • A predictive formula can identify high-risk individuals, enabling targeted interventions.
  • Improving adherence through clinical risk assessment is essential for better MDD management in young populations.